Business

Special Report By David Barboza — The Wire

After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows

Biotech By Adam Feuerstein

A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know

Business By Elizabeth Cooney

A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world

Biotech By Adam Feuerstein

Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug

Biotech By Elizabeth Cooney

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Business By Elizabeth Cooney

‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi

Biotech By Elizabeth Cooney

Startup Spotlight: Aiming to speed precision cancer therapies to children

Special Report By Erin Brodwin and Casey Ross

Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO

Business By Casey Ross

Gawande says leaving Haven CEO job will allow him to focus on Covid-19

Business By Casey Ross and Erin Brodwin

Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?

Special Report By Nicholas Florko and Damian Garde

With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake

Business By Andrew Joseph

Gilead’s remdesivir has seen success against the coronavirus. Now the company has to make enough to supply the world

Business By Andrew Joseph

Patients, drug makers grapple with how to continue cancer trials during the coronavirus

Biotech By Adam Feuerstein

Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis

Biotech By Matthew Herper

Digital event: Combating Covid-19

Business By Andrew Joseph, Adam Feuerstein, Damian Garde and Matthew Herper

Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know

Biotech By Adam Feuerstein

Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer

Business By Jonathan Saltzman — Boston Globe

Boston Scientific cutting hours and pay as revenue drops

Biotech By Adam Feuerstein

The biotech scorecard for the second quarter: 18 stock-moving events to watch

Biotech By Adam Feuerstein

Amarin loses legal fight over heart drug patent; shares sink

Health By Elizabeth Cooney

‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19

Biotech By Adam Feuerstein and Matthew Herper

Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval

Biotech By Adam Feuerstein

Drug makers grounding salespeople as coronavirus impact on business spreads

Biotech By Damian Garde and Adam Feuerstein

How one company made $208 million on an untested coronavirus vaccine

Business By Scott Kirsner — Boston Globe

The Engine at MIT is revving up the potential of ‘tough tech’

Biotech By Jonathan Saltzman — Boston Globe

Thermo Fisher buys Dutch diagnostics company for $11.5 billion

Biotech By Matthew Herper

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven

Biotech By Adam Feuerstein

Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease

Biotech By Adam Feuerstein

With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption